Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(01): 67-68
DOI: 10.4103/sajc.sajc_364_19
Letter to the Editor

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience

Vikas T. Talreja
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Vijay M. Patil
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
› Author Affiliations Financial support and sponsorship: Nill.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
14 December 2020

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol 2018;36:2251-8.
  • 2 Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR. Lorlatinib in patients with ALK-positive non-small cell lung cancer: Results from a global phase 2 study. Lancet Oncol 2018;19:1654-67.